- Home
- ENTX vs ASRT Comparison
ENTX vs ASRT Comparison
Compare ENTX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENTX | ASRT |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 76.0M |
| IPO Year | 2015 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ENTX | ASRT |
|---|---|---|
| Price | $1.50 | $11.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 147.2K | 29.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.07 |
| EPS | ★ 0.18 | N/A |
| Revenue | $181,000.00 | ★ $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | $6.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $0.51 |
| 52 Week High | $3.22 | $12.95 |
Technical Indicators
Market Signals| Indicator | ENTX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 53.65 |
| Support Level | $1.45 | $11.05 |
| Resistance Level | $1.65 | $12.75 |
| Average True Range (ATR) | 0.13 | 0.45 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 66.67 | 52.41 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.